Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: A long-term chart review
Authors:
- Eric KonofalEKEric Konofal
- Yves DauvilliersYves Dauvilliers
- Patricia FrancoPFPatricia Franco
- Smaranda Leu-SemenescuSLSmaranda Leu-Semenescu
- Valérie Cochen De CockVCValérie Cochen De Cock
- Clara O. InocenteCIClara O. Inocente
- Sophie BayardSBSophie Bayard
- Sabine ScholtzSSSabine Scholtz
- Michel LecendreuxMLMichel Lecendreux
- Isabelle ArnulfIAIsabelle Arnulf
- 1 January 2013
- journal article
- clinical trial
- Published by Elsevier in Sleep Medicine
- Vol. 14 (1) , 30-36
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexySleep Medicine, 2011
- Mazindol in the treatment of narcolepsyActa Neurologica Scandinavica, 2009
- An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin−/− mice and patientsNeurobiology of Disease, 2008
- Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central OriginSLEEP, 2007
- EFNS guidelines on management of narcolepsyEuropean Journal of Neurology, 2006
- Therapeutic Effects of Mazindol on NarcolepsySLEEP, 1986
- Amphetamine, mazindol, and fencamfamin in narcolepsy.BMJ, 1985
- 5-Aryl-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ols. Novel class of anorectic agentsJournal of Medicinal Chemistry, 1975
- A multi-centre trial of mazindol (‘Teronac’) in general practice in IrelandCurrent Medical Research and Opinion, 1975
- Clinical Evaluation of the Anorexic Activity and Safety of 42-548 in ChildrenClinical Pediatrics, 1973